Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit on Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Experts reveal potential side effect of Ozempic – and whether we should worry - Researchers found Ozempic-induced weight loss decreased muscle mass by about 10 per cent ...

Once aimed at diabetes patients, drugs like Ozempic are famous for bringing about rapid weight loss. But the injections often ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...